{"id":224087,"date":"2026-08-31T13:49:44","date_gmt":"2026-08-31T08:19:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=224087"},"modified":"2026-08-31T13:49:45","modified_gmt":"2026-08-31T08:19:45","slug":"alembic-pharmaceuticals-overvalued-or-undervalued","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/","title":{"rendered":"Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alembic Pharmaceuticals CMP Rs 819.00 (31 Aug 2026), up 0.68%. PE 23.20 vs industry PE 38.07. ROE 11.89%. 52W range Rs 635.80 to Rs 998.00.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Alembic Pharmaceuticals trades at a price to earnings ratio of 23.20, well below the industry average of 38.07, which points toward undervaluation on a simple multiple basis. The stock&#8217;s 11.89% return on equity and Rs 288.70 book value per share suggest the market may be underpricing the underlying business relative to peers. Whether Alembic Pharmaceuticals is overvalued or undervalued right now depends on whether that discount reflects a genuine risk the market has priced in or simply a lack of investor attention. On valuation multiples alone, the stock currently sits below what the broader sector is priced at.<\/p>\n<\/div>\n<p>Is <a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a> overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 819.00, the stock trades roughly 17.9% below its 52 week high of Rs 998.00 and about 28.8% above its 52 week low of Rs 635.80.<\/p>\n<p>Alembic Pharmaceuticals&#8217;s share price moved up 0.68% in Monday&#8217;s session to Rs 819.00, against a market capitalisation of Rs 16,000 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=valn8\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Alembic_Pharmaceuticals_Valuation_Metrics_Where_Does_the_Stock_Stand\" title=\"Alembic Pharmaceuticals Valuation Metrics: Where Does the Stock Stand?\">Alembic Pharmaceuticals Valuation Metrics: Where Does the Stock Stand?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Is_Alembic_Pharmaceuticals_Overvalued_Based_on_Its_PE_Ratio\" title=\"Is Alembic Pharmaceuticals Overvalued Based on Its P\/E Ratio?\">Is Alembic Pharmaceuticals Overvalued Based on Its P\/E Ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Alembic_Pharmaceuticalss_Financial_Growth_and_Profitability\" title=\"Alembic Pharmaceuticals&#8217;s Financial Growth and Profitability\">Alembic Pharmaceuticals&#8217;s Financial Growth and Profitability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Arguments_That_Alembic_Pharmaceuticals_Could_Be_Overvalued\" title=\"Arguments That Alembic Pharmaceuticals Could Be Overvalued\">Arguments That Alembic Pharmaceuticals Could Be Overvalued<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Arguments_Against_a_Discount\" title=\"Arguments Against a Discount\">Arguments Against a Discount<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Verdict_Is_Alembic_Pharmaceuticals_Overvalued_or_Undervalued_Right_Now\" title=\"Verdict: Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?\">Verdict: Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_Could_Change_This_Valuation_Picture_for_Alembic_Pharmaceuticals\" title=\"What Could Change This Valuation Picture for Alembic Pharmaceuticals?\">What Could Change This Valuation Picture for Alembic Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#FAQs_on_Alembic_Pharmaceuticals_Valuation\" title=\"FAQs on Alembic Pharmaceuticals Valuation\">FAQs on Alembic Pharmaceuticals Valuation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Is_Alembic_Pharmaceuticals_overvalued_or_undervalued_right_now\" title=\"Is Alembic Pharmaceuticals overvalued or undervalued right now?\">Is Alembic Pharmaceuticals overvalued or undervalued right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_is_Alembic_Pharmaceuticalss_current_PE_ratio\" title=\"What is Alembic Pharmaceuticals&#8217;s current PE ratio?\">What is Alembic Pharmaceuticals&#8217;s current PE ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_is_Alembic_Pharmaceuticalss_return_on_equity\" title=\"What is Alembic Pharmaceuticals&#8217;s return on equity?\">What is Alembic Pharmaceuticals&#8217;s return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_is_Alembic_Pharmaceuticalss_52_week_high_and_low\" title=\"What is Alembic Pharmaceuticals&#8217;s 52 week high and low?\">What is Alembic Pharmaceuticals&#8217;s 52 week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Does_Alembic_Pharmaceuticals_have_high_debt\" title=\"Does Alembic Pharmaceuticals have high debt?\">Does Alembic Pharmaceuticals have high debt?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_is_Alembic_Pharmaceuticalss_dividend_yield\" title=\"What is Alembic Pharmaceuticals&#8217;s dividend yield?\">What is Alembic Pharmaceuticals&#8217;s dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#Is_Alembic_Pharmaceuticals_a_good_stock_to_buy_at_current_levels\" title=\"Is Alembic Pharmaceuticals a good stock to buy at current levels?\">Is Alembic Pharmaceuticals a good stock to buy at current levels?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-overvalued-or-undervalued\/#What_is_Alembic_Pharmaceuticalss_price_to_book_ratio\" title=\"What is Alembic Pharmaceuticals&#8217;s price to book ratio?\">What is Alembic Pharmaceuticals&#8217;s price to book ratio?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Valuation_Metrics_Where_Does_the_Stock_Stand\"><\/span><strong>Alembic Pharmaceuticals Valuation Metrics: Where Does the Stock Stand?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Valuation Metric<\/th>\n<th>Alembic Pharmaceuticals<\/th>\n<\/tr>\n<tr>\n<td>CMP (31 Aug 2026)<\/td>\n<td>Rs 819.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 16,000 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>23.20<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>38.07<\/td>\n<\/tr>\n<tr>\n<td>P\/B Ratio<\/td>\n<td>2.82<\/td>\n<\/tr>\n<tr>\n<td>Sector Average P\/B (pharmaceutical)<\/td>\n<td>7.31<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>11.89%<\/td>\n<\/tr>\n<tr>\n<td>Sector Average ROE (pharmaceutical)<\/td>\n<td>12.94%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 35.08<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 288.70<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>1.47%<\/td>\n<\/tr>\n<tr>\n<td>Sector Average Dividend Yield (pharmaceutical)<\/td>\n<td>0.30%<\/td>\n<\/tr>\n<tr>\n<td>52 Week High \/ Low<\/td>\n<td>Rs 998.00 \/ Rs 635.80<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The headline number here is the price to earnings ratio. At 23.20, the Alembic Pharmaceuticals PE ratio is 0.61 times the industry average of 38.07. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P\/B of 2.82 against a sector average of 7.31, and an ROE of 11.89% against a sector average of 12.94%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharmaceuticals_Overvalued_Based_on_Its_PE_Ratio\"><\/span><strong>Is Alembic Pharmaceuticals Overvalued Based on Its P\/E Ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the P\/E ratio alone, Alembic Pharmaceuticals looks undervalued. The stock&#8217;s PE of 23.20 sits well below the industry average of 38.07, which can reflect either a genuine bargain or a market discounting some risk in the business that is not obvious from the ratio itself. Investors relying only on the PE ratio would classify Alembic Pharmaceuticals as cheaper than its peers, but the Alembic Pharmaceuticals PE ratio still needs to be read alongside its return ratios and earnings quality before concluding the stock is a genuine value opportunity.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Alembic Pharmaceuticals&#8217;s Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticalss_Financial_Growth_and_Profitability\"><\/span><strong>Alembic Pharmaceuticals&#8217;s Financial Growth and Profitability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic Pharmaceuticals&#8217;s revenue moved from Rs 6,714.63 crore in FY2025 to Rs 7,399.31 crore in FY2026, a change of 10.2%. Net profit grew from Rs 582.01 crore to Rs 670.83 crore over the same period, a swing of roughly 15.3%.<\/p>\n<p>The Alembic Pharmaceuticals share price has moved alongside this earnings trend, which is part of why the stock now trades at 0.61 times the industry PE of 38.07 rather than a flat multiple.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alembic Pharmaceuticals&#8217;s live share price and valuation ratios.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Arguments_That_Alembic_Pharmaceuticals_Could_Be_Overvalued\"><\/span><strong>Arguments That Alembic Pharmaceuticals Could Be Overvalued<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Sector-wide re-rating risk:<\/strong> If sentiment toward the sector turns, a PE of 23.20 still has room to compress toward the industry average of 38.07.<\/li>\n<li><strong>Limited margin of safety:<\/strong> At Rs 819.00, the stock is only 17.9% below its 52 week high of Rs 998.00, leaving less room for error if earnings disappoint.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Arguments_Against_a_Discount\"><\/span><strong>Arguments Against a Discount<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Low leverage:<\/strong> A debt to equity ratio of 0.25 gives Alembic Pharmaceuticals a comparatively strong balance sheet.<\/li>\n<li><strong>Reasonable income:<\/strong> A dividend yield of 1.47% offers some cushion while the market decides on the growth story.<\/li>\n<li><strong>52 week range context:<\/strong> At Rs 819.00, the stock is 28.8% above its 52 week low of Rs 635.80, showing it has already found some support at lower levels.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Verdict_Is_Alembic_Pharmaceuticals_Overvalued_or_Undervalued_Right_Now\"><\/span><strong>Verdict: Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On balance, Alembic Pharmaceuticals looks undervalued by traditional multiples, trading at a PE of 23.20 against an industry average of 38.07. That gap can close either through the share price catching up or through the business underperforming enough to justify the discount, so the read depends on which explanation fits the company&#8217;s recent earnings trend better. A 11.89% ROE is a reasonable starting point for that judgement, but investors should weigh why the market has kept the stock at a discount before treating the gap as a straightforward opportunity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Could_Change_This_Valuation_Picture_for_Alembic_Pharmaceuticals\"><\/span><strong>What Could Change This Valuation Picture for Alembic Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Two broad scenarios could shift this valuation call on Alembic Pharmaceuticals in either direction. On the upside, the market recognising the gap between the PE of 23.20 and the industry average of 38.07, which would show up as the share price re-rating higher without a change in earnings. On the downside, a genuine deterioration in the business that justifies the current discount, in which case the low PE would turn out to be a fair reflection of risk rather than a bargain. Investors watching the Alembic Pharmaceuticals share price over the next few quarters should track whether reported ROE holds near 11.89% and whether the PE gap versus the industry average of 38.07 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic Pharmaceuticals&#8217;s numbers point to a stock that is undervalued on headline multiples, though its return ratios help explain part of the gap. Investors tracking the Alembic Pharmaceuticals share price should watch whether earnings growth can keep pace with the current PE of 23.20, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Alembic_Pharmaceuticals_Valuation\"><\/span><strong>FAQs on Alembic Pharmaceuticals Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharmaceuticals_overvalued_or_undervalued_right_now\"><\/span><strong>Is Alembic Pharmaceuticals overvalued or undervalued right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Based on a PE ratio of 23.20 against an industry average of 38.07, Alembic Pharmaceuticals currently looks undervalued on relative valuation. Its 11.89% ROE is an important part of the picture alongside the PE ratio.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alembic_Pharmaceuticalss_current_PE_ratio\"><\/span><strong>What is Alembic Pharmaceuticals&#8217;s current PE ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals&#8217;s price to earnings ratio stands at 23.20, compared with an industry average PE of 38.07.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alembic_Pharmaceuticalss_return_on_equity\"><\/span><strong>What is Alembic Pharmaceuticals&#8217;s return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals generates a return on equity of 11.89%, against a sector average of 12.94% among pharmaceutical peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alembic_Pharmaceuticalss_52_week_high_and_low\"><\/span><strong>What is Alembic Pharmaceuticals&#8217;s 52 week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals&#8217;s 52 week high is Rs 998.00 and its 52 week low is Rs 635.80. The stock currently trades around Rs 819.00, roughly 17.9% below its high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_Alembic_Pharmaceuticals_have_high_debt\"><\/span><strong>Does Alembic Pharmaceuticals have high debt?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals carries a debt to equity ratio of 0.25, which is low for its sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alembic_Pharmaceuticalss_dividend_yield\"><\/span><strong>What is Alembic Pharmaceuticals&#8217;s dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals offers a dividend yield of 1.47% at the current share price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharmaceuticals_a_good_stock_to_buy_at_current_levels\"><\/span><strong>Is Alembic Pharmaceuticals a good stock to buy at current levels?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals&#8217;s current valuation suits investors who agree with the undervalued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Alembic_Pharmaceuticalss_price_to_book_ratio\"><\/span><strong>What is Alembic Pharmaceuticals&#8217;s price to book ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals trades at a price to book ratio of 2.82, compared with a sector average of 7.31 among pharmaceutical peers.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharmaceuticals trades at a PE of 23.20 versus an industry average of 38.07. We break down its ROE, debt, and valuation ratios to assess if the stock is overvalued or undervalued right now.<\/p>\n","protected":false},"author":35,"featured_media":224086,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-224087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["224086"],"_edit_lock":["1788164389:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["70"],"rank_math_title":["Alembic Pharmaceuticals Share Valuation: Overvalued or Undervalued?"],"rank_math_description":["Is Alembic Pharmaceuticals overvalued or undervalued right now? A look at its PE ratio, industry PE, ROE and book value versus CMP Rs 819.00 to judge the stock's valua..."],"rank_math_focus_keyword":["Alembic Pharmaceuticals"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["40518"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/alembic-pharmaceuticals-overvalued-or-undervalued.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=224087"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224087\/revisions"}],"predecessor-version":[{"id":224141,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224087\/revisions\/224141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/224086"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=224087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=224087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=224087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}